Glioblastoma (GBM) is the most common primary malignant brain tumor in adults.
Regardless of ideal multidisciplinary treatment, including maximal surgical resection …

The DNA repair protein O6‐Methylguanine‐DNA methyltransferase (MGMT) is suggested to
be associated with resistance to alkylating agents such as Temozolomide which is being …

Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …

Introduction Despite aggressive treatment with chemoradiotherapy and maximum surgical
resection, survival in patients with glioblastoma (GBM) remains poor. Ongoing efforts are …

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …

Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in
the United States for recurrent GBM in 2009. In order to review the therapeutic effect of …

Glioblastoma (GBM) is the most common and highly lethal primary malignant brain tumor in
adults. There is a dire need for easily accessible, noninvasive biomarkers that can delineate …

The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-
angiogenic cancer therapy are major issues in almost all current concepts of both cancer …

Background. Glioblastoma (GBM) is the most common primary brain tumor, with dismal
prognosis. The failure of drug–radiation combinations with promising preclinical data to …

New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …